
Loading, please wait...

Loading, please wait...

Aflatoxin B1 (AFB1) represents a persistent environmental threat, particularly in regions like India where food storage conditions often favor fungal growth. Chronic exposure significantly increases the risk of hepatocellular carcinoma and acute liver damage. Recent research highlights the therapeutic potential of l-Aspartic acid liver injury mitigation. This amino acid exhibits antioxidant and anti-inflammatory properties that may counteract toxin-induced hepatotoxicity through the gut-liver axis.
The study evaluated the effects of dietary l-Aspartic acid (l-Asp) supplementation on rabbits exposed to AFB1. Researchers assigned fifty rabbits to various groups, providing different concentrations of l-Asp (0.5%, 1.0%, and 1.5%) for 21 days. Significantly, the results demonstrated that l-Asp pretreatment alleviated impairments in growth performance and improved serum biochemical parameters. Furthermore, the 1.0% dosage emerged as the most effective intervention for protecting hepatic tissue from damage.
Furthermore, the treatment successfully reduced hepatic collagen fiber deposition and ameliorated damage to the ileal barrier. These findings suggest that l-Asp acts beyond simple antioxidant support. It actively restores the composition of gut microbiota and normalizes bile acid metabolism. Consequently, this intervention addresses the complex interactions within the gut-liver axis that usually exacerbate AFB1 poisoning. Notably, the normalized bile acid metabolism correlated with the regulation of key metabolic receptors.
Notably, AFB1 exposure typically disrupts intestinal homeostasis and various metabolic pathways. However, l-Asp pretreatment regulated key metabolic receptors to maintain a healthy microflora balance. Moreover, it normalized the levels of various bile acids that are often dysregulated during liver injury. Therefore, this nutritional strategy offers a multifaceted approach to protecting hepatic health from dietary toxins. This work provides a clear rationale for future studies to further elucidate these molecular mechanisms in human clinical settings.
Research indicates that l-Aspartic acid helps mitigate liver injury by reducing oxidative stress, repairing the intestinal barrier, and restoring healthy gut microflora.
The study established a 1.0% dietary supplementation of l-Aspartic acid as an effective, gut-liver axis-targeted concentration for alleviating the toxic effects of Aflatoxin B1.
Aflatoxins disrupt the gut barrier and microbiota, allowing toxins and harmful metabolites to reach the liver. Interventions like l-Aspartic acid protect the liver by first stabilizing intestinal health and bile acid metabolism.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Kong D et al. l-Aspartic acid alleviates aflatoxin B1-induced liver injury by regulating intestinal microflora homeostasis and bile acid metabolism. J Sci Food Agric. 2026 Mar 09. doi: 10.1002/jsfa.70557. PMID: 41803008.
Murugavel KG et al. Role of Aflatoxin B1 as A Risk for Primary Liver Cancer in India. Austin J Cancer Clin Res. 2023 Nov 15.
Li et al. Research progress in toxicological effects and mechanism of aflatoxin B1 toxin. PeerJ. 2022 Aug 04. doi: 10.7717/peerj.13850.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A study highlights how l-Aspartic acid helps mitigate liver injury caused by Aflatoxin B1 by regulating gut microflora and bile acid metabolism....
4 months ago

A cross-sectional analysis from the Electronic Framingham Heart Study reveals that a higher daily heart rate per step ratio is associated with lower composite cognitive scores in older adults, highlighting smartwatch metrics as valuable tools for detecting subclinical cardiovascular factors linked to brain health.
Today

A multicenter study identifies a three-metabolite gut microbiota panel (3-hydroxydecanoic acid, γ-Glu-Leu, and propionic acid) for early risk stratification of gestational diabetes mellitus in the first trimester, offering superior predictive accuracy over standard clinical risk factors before 24 weeks.
Today

A comprehensive 50-year study reveals an 82% decrease in overall US stroke mortality from 1970 to 2023. While ischemic and hemorrhagic stroke deaths dropped significantly due to clinical and public health advances, racial disparities persist, with Black adults continuing to experience the highest mortality rates.
Today

A cadaveric study compares the biomechanical strength, load-to-failure, and stiffness of tape-augmented all-soft tissue quadriceps tendon autografts against quadrupled semitendinosus constructs in ACL reconstruction, providing crucial insights for orthopaedic surgeons regarding graft selection and fixation.
Today

Discover clinical pitfalls in diagnosing SGLT2 inhibitor ketoacidosis in the ICU. Learn how cardiac surgery and GLP-1 agonist interactions trigger euglycemic DKA and explore management strategies.
Yesterday